Tech Company Financing Transactions
Kypha Funding Round
Kypha, operating out of St. Louis, secured $4 million in investment from Arsenal Capital Management and private investors.
Transaction Overview
Company Name
Announced On
12/21/2018
Transaction Type
Venture Equity
Amount
$4,000,000
Round
Series A
Investors
Arsenal Capital Management (Lead Investor) (Peter Reinecke)
Proceeds Purpose
The Series A funding is being used to complete integration and expand manufacturing capacity of recently acquired Biosensia and its ISO 13485-certified facilities in Dublin, Ireland; to support commercial launch of additional Kypha tests; and to expand partnerships with leading-edge pharmaceutical companies advancing several promising new blockbuster therapies targeting complement, a central arm of the immune system.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
4340 Duncan Ave. 204
St. Louis, MO 63110
USA
St. Louis, MO 63110
USA
Phone
Website
Email Address
Overview
Kypha is an early-stage life sciences company developing leading-edge technology and clinically useful products to improve the way autoimmune and inflammatory disorders are monitored and treated.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
James Merselis
Chief Executive Officer
Chad Stiening
Chief Operating Officer
Niamh O'Luanaigh
Chief Scientific Officer
Martin Schmidt
Browse more venture capital transactions:
Prev: 12/21/2018: Boosted venture capital transaction
Next: 12/21/2018: Gamelearn venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs